US-based Phibro Animal Health Corporation, a global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products, acquired the assets of KoVax Ltd., an Israel-based developer and manufacturer of vaccines for the global aquaculture market, on Dec.6.
The acquisition strengthens Phibro’s position in fish vaccine innovation and expands its portfolio of aquaculture products.
KoVax’s research and development (R&D) team has joined Phibro’s biological R&D team, and will focus on developing a pipeline of vaccines for the aquaculture market.
